John Porter, DO
Internal Medicine · Montgomery, ALNPI 1205182508
Payments from drug & device makers
Across 1,392 payments — averaging $226.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$294K
- AstraZeneca$9K
- Boehringer Ingelheim$4K
- Chiesi USA, Inc.$4K
- GSK$1K
- Amarin Pharma, Inc.$603
- plus $3K from 23 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 1,035 | $293,845 |
| AstraZeneca | 32 | $9,084 |
| Boehringer Ingelheim | 14 | $3,919 |
| Chiesi USA, Inc. | 2 | $3,836 |
| GSK | 78 | $1,169 |
| Amarin Pharma, Inc. | 39 | $603 |
| Novo Nordisk | 32 | $543 |
| Pfizer | 23 | $373 |
| Astellas Pharma US Inc | 16 | $326 |
| Lilly USA, LLC | 23 | $302 |
| AbbVie(2 entities) | 9 | $198 |
| Amgen(2 entities) | 11 | $197 |
| Johnson & Johnson(2 entities) | 11 | $175 |
| Sanofi-aventis U.S. LLC | 10 | $157 |
| Sumitomo Pharma America, Inc. | 8 | $150 |
| Exact Sciences | 7 | $120 |
| Bayer | 6 | $102 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $100 |
| Novartis | 7 | $99 |
| Kowa Pharmaceuticals America, Inc. | 7 | $91 |
| Sunovion Pharmaceuticals Inc. | 6 | $83 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $45 |
| Lexicon Pharmaceuticals, Inc. | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Hologic Sales And Service, LLC | 1 | $18 |
| Merck | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Bioventus LLC | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
How this compares
$315,641 in reported general payments places this provider in the 95th percentile of 1,533 internal medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other internal medicine in Montgomery
- Joel McCloudMontgomery$27K
- John JerniganMontgomery$25K
- Harry StuddardMobile$12.9M
- Almena FreeAnniston$12.7M
- Hayes WilliamsVestavia$10.4M
- David DeatkineBirmingham$8M
- James SullivanBirmingham$6M
- Ramy TomaBirmingham$5.1M
- Barry McLeanHomewood$4M
- William KirbyBirmingham$2.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.